Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Georg Stöckl"'
Publikováno v:
Cardiology and Therapy, Vol 8, Iss 2, Pp 317-328 (2019)
Abstract Introduction The antianginal effectiveness of ivabradine administration in addition to beta-blockers has been shown in patients with stable angina. The first fixed-dose combination (FDC) of ivabradine and metoprolol is now available and its
Externí odkaz:
https://doaj.org/article/0fff859dd4fd4b478942484d68433913
Publikováno v:
Advances in Therapy
Introduction In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of ivabradine with or without beta blocker (BB) were evaluated in patients with chronic stable angina p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::978245272f48495b8a73d7c035f02fba
https://doi.org/10.1007/s12325-016-0377-7
https://doi.org/10.1007/s12325-016-0377-7
Autor:
Henning Ebelt, Florian Höpfner, Sebastian Nuding, Ursula Müller-Werdan, Georg Stöckl, Karl Werdan
Publikováno v:
Cardiology. 133:83-90
Objectives: Elevated heart rate can increase myocardial oxygen demand and reduce myocardial perfusion, provoking myocardial ischemia and angina symptoms. We evaluated adding ivabradine to the therapy of patients on metoprolol. Methods: ADDITIONS (prA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e1b8a2dd991ec34010e6410753976c7
https://doi.org/10.1159/000439584
https://doi.org/10.1159/000439584
Autor:
Sebastian Nuding, Henning Ebelt, Ursula Müller-Werdan, Georg Stöckl, Florian Höpfner, Karl Werdan
Publikováno v:
Advances in Therapy
Introduction The anti-anginal efficacy of ivabradine is well established. We describe a post hoc analysis in the ADDITIONS database to investigate effectiveness and tolerability of ivabradine in combination with beta-blocker in patients with angina w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59627e045b3b8115c4a3b88418e5681d
https://doi.org/10.1007/s12325-015-0182-8
https://doi.org/10.1007/s12325-015-0182-8
Autor:
Georg Stöckl, Dimitar Divchev
Publikováno v:
Cardiology and Therapy
Introduction In this prospective, multicenter, observational cohort study, the effectiveness and tolerability of the first fixed-dose combination (FDC) formulation of the selective heart rate reducing agent ivabradine and the beta-blocker metoprolol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0918d20defbe3f4c7be25e7a0b15e10
https://pubmed.ncbi.nlm.nih.gov/29116618
https://pubmed.ncbi.nlm.nih.gov/29116618
Publikováno v:
Advances in Therapy
Introduction In the prospective, open-label multicenter INTENSIFY study, the effectiveness and tolerability of ivabradine as well as its impact on quality of life (QOL) in chronic systolic heart failure (CHF) patients were evaluated over a 4-month pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b1d1fac1c923c32087db6ab4d2bcda1
https://doi.org/10.1007/s12325-014-0147-3
https://doi.org/10.1007/s12325-014-0147-3
Publikováno v:
Vascular Health and Risk Management
A high resting heart rate (≥70-75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c13917ff386587407f24a1ad79e57fde
https://pubmed.ncbi.nlm.nih.gov/27895488
https://pubmed.ncbi.nlm.nih.gov/27895488
Autor:
Stefan Perings, Ralf Köster, Thomas Meinertz, Georg Stöckl, Karl Werdan, Malte Kelm, Ursula Müller-Werdan
Publikováno v:
Cardiology. 135(3)
Objectives: The efficacy of ivabradine has been demonstrated in different subpopulations of stable angina patients in randomized clinical trials. This study explored its effectiveness in subpopulations seen in clinical practice as they often differ f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233188f3eb3aeb608dd7fbed83d4b8f9
https://pubmed.ncbi.nlm.nih.gov/27333284
https://pubmed.ncbi.nlm.nih.gov/27333284
Autor:
Ursula Müller-Werdan, Sebastian Nuding, Henning Ebelt, Additions Study Investigators, Florian Höpfner, Georg Stöckl, Karl Werdan
Publikováno v:
Experimental gerontology. 59
Clinical trials have proven the anti-anginal and anti-ischemic efficacy of the pacemaker current inhibitor ivabradine in combination with beta-blockers in patients with stable angina pectoris (AP). This retrospective subgroup analysis of the ADDITION
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49322e40e011f8d1ba4311fbb99c816b
https://pubmed.ncbi.nlm.nih.gov/25193811
https://pubmed.ncbi.nlm.nih.gov/25193811
Publikováno v:
The EMBO journal. 26(21)
Cardiac pacemaking involves a variety of ion channels, but their relative importance is controversial and remains to be determined. Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, which underlie the I(f) current of sinoatrial cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b9585de792b3704804c26993b481299
https://pubmed.ncbi.nlm.nih.gov/17914461
https://pubmed.ncbi.nlm.nih.gov/17914461